| February 6, 2014 | ISSUE NUMBER 337 VOL 2 |
Sales
End of the Road for the American Rx Salesperson?
On the healthcare cost-of-operating spreadsheet, the expense for Rx care, as with all healthcare services, must be reduced. Most Rx drugs that are being prescribed are generic; and all drugs, whether brand or generic, are being subjected to dramatic demands for discounted pricing. Where does this leave the Rx salesperson, asks Tom Norton...Read more
Event
Compliance Congress Offers Some Carrots, Mostly Sticks
FDA regulators, pharma industry executives and Department of Justice attorneys speaking at CBI's 11th annual Pharmaceutical Compliance Congress emphasized the importance of company culture in preventing non-compliance, and anticipated an increase in global enforcement efforts...Read more
NSF Health Sciences (formerly Becker & Associates) helps clients meet and exceed FDA requirements for developing, testing and marketing innovative healthcare products. NSF offers quality services in the following practice areas:
- Regulatory – Approval Strategy, FDA Interactions, 510(k), PMA, NDA
- Compliance – Quality Systems, cGMP’s, Form 483s, Warning Letters
- Trials – Preclinical and Clinical Study Design
- Analysis – Due Diligence, Litigation Support.
 Read more:
Capitol Hill
Waxman Retirement is Tip of the Iceberg
The recent announcement that Rep. Henry Waxman is retiring marks the end of a 40-year career on Capitol Hill. And it is just the beginning of a major shake-up of the Washington health policy world this year, writes Jill Wechsler ...Read more
Regulatory
FDA Guidances, OIG Investigations to Shape Drug Marketing, Research
Marketers may see further advice from the Food and Drug Administration in the coming year that clarifies how they can use social media. At the same time, the Office of the Inspector General (OIG) of the Department of Health and Human Services will be busy investigating a number of issues related to drug regulation and reimbursement ...Read more
Europe
Growing Pains: The European Medicines Agency at 20
Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014 ...Read more
eBook
Pharmaceutical Executive’s Digital Marketing Three eBook & Video Combo
Pharmaceutical Executive brings you the perfect combination of resources to increase your digital marketing IQ: an eBook with 10 must-read topics and more than four hours of in-depth video presentations by marketing experts Augustine Fou, Mike Moran and Mark Schaefer ...Read more
Outlook
Pharm Exec’s Annual Industry Outlook 2014
For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. As our annual industry outlook confirms, it’s time to be decisive — muddling through is so ‘yesterday’ ...Read more
|
|
|
|
 //Joseph Loccalzo, MD, PhD, joined the Board of Directors of Isis Pharmaceuticals, Inc. (Carlsbad, CA).//Catabasis Pharmaceuticals Inc. (Cambridge, MA) announced the appointment of Kenneth M. Bate to its Board of Directors as an Independent Director.//The EY Global Life Sciences Center (Boston, MA) announced two new appointments: Mitchell Cohen was named Global Life Sciences Tax Services Leader, and Kimberley Ramko was appointed Global Life Science Advisory Services Leader. The company also reported that Scott Bruns will continue his role of Global Life Sciences Assurance Services Leader, and Jeffrey Greene will continue to serve as Global Life Sciences Transactions Advisory Services Leader.//GenomOncology (Westlake, OH) announced investment from TriStar Technology Ventures (Nashville, TN), as well as the appointment of John Doulis, CIO of TriStar’s partner fund, MedCare Investment Funds to the company’s Board Of Directors.// |
|
|
|
|
|
